Location History:
- Duebendorf, CH (2019 - 2022)
- Schlieren, CH (2020 - 2023)
Company Filing History:
Years Active: 2019-2025
Title: Maria Amann: Innovator in Bispecific Antibody Development
Introduction
Maria Amann, located in Dübendorf, Switzerland, is a prominent inventor known for her significant contributions to the field of biochemistry and immunology. With a remarkable portfolio of 13 patents, she is recognized for her innovative work on bispecific antibodies, which have the potential to revolutionize therapeutic approaches to various diseases.
Latest Patents
Among her latest inventions, Maria has developed two notable patents. The first is titled "Bispecific Antibodies Specific for OX40." This invention focuses on creating novel bispecific antigen-binding molecules that can bind to specific target cell antigens and costimulatory TNF receptor family members. It also covers the Fc domain composed of a stable association of two subunits, along with methods for producing and using these innovative molecules.
The second patent, "Bispecific 2+1 Contorsbodies," describes bispecific antibodies that consist of two fusion polypeptides. These polypeptides include two antigen-binding domains targeting a first antigen and one binding domain for a second target. This patent outlines the methods for producing these innovative molecules and their application in the scientific field.
Career Highlights
Maria Amann is an influential figure in the pharmaceutical industry and currently works at Hoffmann-La Roche Inc., a leading global healthcare company. Her work has made substantial advancements in the development of new therapeutic strategies, especially in the field of antibody technology. The innovative nature of her patents showcases her dedication to improving medical treatments and patient care.
Collaborations
Throughout her career, Maria has collaborated with talented individuals, including her colleagues Sandra Grau-Richards and Christian Klein. These collaborations foster a creative and productive environment, contributing to the successful development of groundbreaking biopharmaceutical solutions.
Conclusion
Maria Amann's contributions to bispecific antibody technology underscore her role as a pioneering inventor in the biochemistry sector. With 13 patents to her name and ongoing collaborations, she continues to push the boundaries of innovation, impacting the future of therapeutic interventions. Her work exemplifies the power of creativity and teamwork in advancing scientific research and healthcare solutions.